Showing results 1 to 1 of 1
| Title | Author(s) | Issue Date | |
|---|---|---|---|
A Phase IIIb open-label, single-arm study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: An interim analysis. Proceeding/Conference:World Lung Cancer Conference, 2017 | 2017 |